VIRACTA THERAPEUTICS INC (VIRX)

Company Profile

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. The company is headquartered in Cardiff-By-The-Sea, California and currently employs 41 full-time employees. The company went IPO on 2005-09-27. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label phase II basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II trial for the treatment of EBV+recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its Vecabrutinib is a selective, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK). VRx-510 is its preclinical-stage PDK-1 inhibitor. The company is also investigating in pre-clinical studies the use of its epigenetic drug candidate, nanatinostat.

Company Info

VIRACTA THERAPEUTICS INC

2533 S Coast Hwy 101, Suite 210

Cardiff-by-the-Sea CALIFORNIA 94080

P: 18584008470

CEO: Parvinder Hyare

Employees: 41

Website: https://www.viracta.com/